Sabra Health Care REIT, Inc. (SBRA)
NASDAQ: SBRA · Real-Time Price · USD
19.86
0.00 (0.00%)
Apr 2, 2026, 4:00 PM EDT - Market closed
Sabra Health Care REIT Stock Forecast
Stock Price Forecast
The 8 analysts that cover Sabra Health Care REIT stock have a consensus rating of "Buy" and an average price target of $22, which forecasts a 10.78% increase in the stock price over the next year. The lowest target is $21 and the highest is $24.
Price Target: $22 (+10.78%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sabra Health Care REIT stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 5 | 6 | 6 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 8 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $21 → $22 | Buy | Maintains | $21 → $22 | +10.78% | Mar 26, 2026 |
| Truist Securities | Truist Securities | Hold Maintains $21 → $22 | Hold | Maintains | $21 → $22 | +10.78% | Mar 13, 2026 |
| Scotiabank | Scotiabank | Hold Maintains $20 → $21 | Hold | Maintains | $20 → $21 | +5.74% | Mar 2, 2026 |
| UBS | UBS | Hold Maintains $20 → $21 | Hold | Maintains | $20 → $21 | +5.74% | Feb 19, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $21 → $24 | Strong Buy | Maintains | $21 → $24 | +20.85% | Feb 18, 2026 |
Financial Forecast
Revenue This Year
833.97M
from 775.76M
Increased by 7.50%
Revenue Next Year
909.64M
from 833.97M
Increased by 9.07%
EPS This Year
0.77
from 0.64
Increased by 19.53%
EPS Next Year
0.81
from 0.77
Increased by 5.33%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 960.4M | 1.1B | |||
| Avg | 834.0M | 909.6M | |||
| Low | 721.7M | 770.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 23.8% | 28.4% | |||
| Avg | 7.5% | 9.1% | |||
| Low | -7.0% | -7.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.88 | 0.86 | |
| Avg | 0.77 | 0.81 | |
| Low | 0.69 | 0.75 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 37.8% | 12.5% | |
| Avg | 19.5% | 5.3% | |
| Low | 7.2% | -1.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.